Literature DB >> 14670344

M. tuberculosis persistence, latency, and drug tolerance.

James E Gomez1, John D McKinney.   

Abstract

The success of Mycobacterium tuberculosis as a pathogen is largely attributable to its ability to persist in host tissues, where drugs that are rapidly bactericidal in vitro require prolonged administration to achieve comparable effects. Latency is a frequent outcome of untreated or incompletely treated M. tuberculosis infection, creating a long-standing reservoir of future disease and contagion. Although the interactions between the bacterium and its host that result in chronic or latent infection are still largely undefined, recent years have seen a resurgence of interest and research activity in this area. Here we review some of the classic studies that have led to our current understanding of M. tuberculosis persistence, and discuss the varied approaches that are now being brought to bear on this important problem.

Entities:  

Mesh:

Year:  2004        PMID: 14670344     DOI: 10.1016/j.tube.2003.08.003

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  216 in total

1.  Grand challenge commentary: Exploiting single-cell variation for new antibiotics.

Authors:  Erick Strauss
Journal:  Nat Chem Biol       Date:  2010-12       Impact factor: 15.040

2.  Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals.

Authors:  Sarah Schmidt Grant; Benjamin B Kaufmann; Nikhilesh S Chand; Nathan Haseley; Deborah T Hung
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

3.  Identification of a diacylglycerol acyltransferase gene involved in accumulation of triacylglycerol in Mycobacterium tuberculosis under stress.

Authors:  Tatiana D Sirakova; Vinod S Dubey; Chirajyoti Deb; Jaiyanth Daniel; Tatiana A Korotkova; Bassam Abomoelak; Pappachan E Kolattukudy
Journal:  Microbiology (Reading)       Date:  2006-09       Impact factor: 2.777

4.  Examining the basis of isoniazid tolerance in nonreplicating Mycobacterium tuberculosis using transcriptional profiling.

Authors:  Griselda Tudó; Ken Laing; Denis A Mitchison; Philip D Butcher; Simon J Waddell
Journal:  Future Med Chem       Date:  2010-08       Impact factor: 3.808

5.  Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates.

Authors:  Zhifang Xie; Noman Siddiqi; Eric J Rubin
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

6.  Intragranulomatous necrosis in pulmonary granulomas is not related to resistance against Mycobacterium tuberculosis infection in experimental murine models induced by aerosol.

Authors:  Evelyn Guirado; Sergi Gordillo; Olga Gil; Jorge Díaz; Gustavo Tapia; Cristina Vilaplana; Vicenç Ausina; Pere-Joan Cardona
Journal:  Int J Exp Pathol       Date:  2006-04       Impact factor: 1.925

7.  Kinetics and inhibition of nicotinamidase from Mycobacterium tuberculosis.

Authors:  Derrick R Seiner; Subray S Hegde; John S Blanchard
Journal:  Biochemistry       Date:  2010-11-09       Impact factor: 3.162

Review 8.  Bacterial persistence: some new insights into an old phenomenon.

Authors:  R Jayaraman
Journal:  J Biosci       Date:  2008-12       Impact factor: 1.826

9.  Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.

Authors:  W P Drake; B W Richmond; K Oswald-Richter; C Yu; J M Isom; J A Worrell; G R Shipley
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2013-11-25       Impact factor: 0.670

10.  Strengths and weaknesses of diagnostic tools for tuberculous uveitis.

Authors:  Daniel V Vasconcelos-Santos; Manfred Zierhut; Narsing A Rao
Journal:  Ocul Immunol Inflamm       Date:  2009 Sep-Oct       Impact factor: 3.070

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.